<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00441415</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29058</org_study_id>
    <nct_id>NCT00441415</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris</brief_title>
  <official_title>Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Compared to Clindamycin 0.1% / Benzoyl Peroxide 5% Gel in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the non-inferior efficacy of Adapalene 0.1% /
      Benzoyl Peroxide 2.5% Gel when compared to Clindamycin 1% / Benzoyl Peroxide 5% Gel in
      Subjects with acne vulgaris after a 12-week treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from Baseline in total lesion count (sum of non inflammatory and inflammatory lesions) at week 12.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline in total inflammatory and non inflammatory lesion counts at each intermediate visit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global severity assessment at each post Baseline visit</measure>
  </secondary_outcome>
  <enrollment type="Actual">272</enrollment>
  <condition>Acne Vulgaris</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene BPO</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Male or female Subjects of any race, between the age of 12 and 35 years inclusive, with
        acne vulgaris, meeting specific inclusion/exclusion criteria.

        Main inclusion criteria:

          1. Male or female Subjects of any race, aged 12 to 35 years inclusive, with facial acne
             vulgaris,

          2. Subjects with a minimum of 20 inflammatory lesions (papules and pustules) on the face,

          3. Subjects with a minimum of 30 and a maximum of 100 non-inflammatory lesions (open
             comedones and closed comedones) on the face, excluding the nose.

        Main exclusion criteria:

          1. Subjects with acne cystic lesions,

          2. Subjects with acne conglobate, acne fulminancy, secondary acne (chloracne,
             drug-induced acne, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth ARTHUR, MD</last_name>
    <affiliation>Helendale Dermatology - Rochester NY - 585-266-5420</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alicia BUCKO, MD</last_name>
    <affiliation>Academic Dermatology Associates - Albuquerque NM - 505-247-4220</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul YAMAUCHI, MD</last_name>
    <affiliation>Clinical Research Specialists, Inc. - Santa Monica CA - 310-828-8887</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven E. KEMPERS, MD</last_name>
    <affiliation>Minnesota Clinical Study Center - Fridley MN - 763-571-4200</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald GOLLNICK, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Otto-von-Guericke University - Magdeburg - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvonne FRAMBACH, MD</last_name>
    <affiliation>Universitatsklinikum - Lubeck - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael MEURER, MD</last_name>
    <affiliation>Dresden University - Dresden - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christos ZOUBOULIS, MD</last_name>
    <affiliation>Hautklinik und Immunologisches Zentrum des St√§dtischen Klinikum - Dessau - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland KAUFMANN, MD</last_name>
    <affiliation>Zentrum fur Dermatoligie und Venerologie - Frankfurt - Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas SCHWARZ, MD</last_name>
    <affiliation>Klinik fur Dermatologie, Venerologie und Allerologie - Kiel - Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Paul YAMAUCHI</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven E. KEMPERS</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Alicia BUCKO</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth ARTHUR</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.galderma.com/</url>
  </link>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2007</study_first_submitted>
  <study_first_submitted_qc>February 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2007</study_first_posted>
  <last_update_submitted>August 5, 2008</last_update_submitted>
  <last_update_submitted_qc>August 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

